Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.83 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.83 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.83 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.83 |
| ▸ | MAOA | P21397 | 1/20 | 0.83 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.83 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.83 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.83 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amphetamine SCHEMBL28357493 | 0.91 | TAAR1 (0.83) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL28990193 | 0.91 | TAAR1 (0.91) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL15094242 | 0.91 | SLC6A2 (1.00) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Levamfetamine SCHEMBL2636 | 0.91 | SLC6A2 (1.00) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL8858 | 0.91 | SLC6A2 (1.00) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL13747801 | 0.91 | SLC6A2 (1.00) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL910141 | 0.91 | SLC6A2 (1.00) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL13746679 | 0.91 | SLC6A2 (1.00) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL8859 | 0.91 | SLC6A2 (1.00) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Levamfetamine SCHEMBL9673275 | 0.91 | SLC6A2 (1.00) | TAAR1SLC6A2SLC6A4MAOASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612056-B2 | schizophrenia, emesis, anxiety and depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, pre-eclampsia, nociception, neuropathic pain, pancreatitis, neurogenic inflammation, asthma, chronic obstructive pulmonary disease (COPD) and urinary incontinence | JENSSEN PHARMACEUTICA N.V. (BE) | 2009-11-03 | — | — | US | disclosed |
| US-20070254904-A1 | Substituted Diaza-Spiro-[4.5]-Decane Derivatives and Their Use as Neurokinin Antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | US | disclosed |
| US-5587273-A | Molecularly imprinted materials, method for their preparation and devices employing such materials | ADVANCED MICROBOTICS CORPORATION (US) | 1996-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254904-A1 | Substituted Diaza-Spiro-[4.5]-Decane Derivatives and Their Use as Neurokinin Antagonists | NPSR1, PROKR2, PROKR1 | SLC6A2 1335/4885SLC6A3 407/4885TAAR1 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.